September 2024 - Page 2 of 2 - BioMedWire (BMW)

FridaySep 13, 2024 10:00 am

WHO Review Says No Link Between Mobile Phones, Brain-Cancer Development

A recently conducted review has determined that there’s no correlation between the use of mobile phones and a heightened risk of acoustic neuromas, meningiomas and gliomas. The review also found no correlation between mobile phone use and leukemia or salivary and pituitary cancers. Mobile phones are low-powered transmitters of radiofrequency-electromagnetic fields. They work by transmitting radio waves to their destinations via cell towers. The review included 63 studies conducted between 1994 and 2022 and published in more than 20 countries. Each study examined how exposure to radio frequency-electromagnetic fields transmitted by electronic devices, primarily mobile phones, affected the health of…

WednesdaySep 11, 2024 10:00 am

Does Multiple Sclerosis Reduce Risk of Developing Dementia?

Multiple sclerosis is a chronic illness of the central nervous system that affects an individual’s immune system, causing it to attack the body by mistake. On the other hand, Alzheimer’s is a neurodegenerative illness that affects an individual’s memory as well as cognitive function. Now, a new study has found that patients with multiple sclerosis are less likely to present with molecular signs of Alzheimer’s, suggesting a protective component that could help develop new treatments. The study was carried out by researchers at the Washington University School of Medicine in St. Louis. It was based on an idea of Dr.…

WednesdaySep 11, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference

The H.C. Wainwright 26th Annual Global Investment Conference is being held on-line and in person, Sept. 9-11. Clene management will give a virtual presentation of the company’s most recent achievements and results and will hold one-on-one investor meetings. Lead drug candidate CNM-Au8 has been shown to restore and protect neurological function, offering new hope for patients with neurodegenerative conditions. The company is seeking FDA approval to file a new drug application for CNM-Au8, using the accelerated approval pathway for treatment of ALS. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to…

MondaySep 09, 2024 10:00 am

Frailty Trajectories Unaffected by Enrollment in Medicare Advantage

Medicare Advantage (MA) has become popular in recent years, with 2023 figures showing that the plans have more than 29 million enrollees. This figure represents 51% of all beneficiaries under Medicare. Plans under Medicare Advantage have lower premiums while covering additional benefits such as dental and vision. However, enrollees have access to a limited network of practitioners in comparison to enrollees of conventional Medicare. Additionally, beneficiaries of Medicare Advantage differ from beneficiaries of traditional Medicare across both socioeconomic and health status, with enrollees of the former plans being more likely to have lower incomes and be Hispanic or Black. Now,…

FridaySep 06, 2024 10:00 am

Expert Says Alzheimer’s Disease Could Be an Autoimmune Illness

Alzheimer’s is a progressive illness that affects an individual’s behavior, thinking and memory. In the early stages, patients present with mild forgetfulness, and this progresses as time goes by, with patients at the late stage losing many physical abilities, among other things. This common form of dementia affects more than 50 million individuals around the globe. Often, individuals living with the illness are unable to recognize their spouses or even their own children when the illness is in its final stages. While the illness has no cure, this hasn’t deterred researchers from looking for one. Previous research had determined that…

FridaySep 06, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets

With a focus on improving mitochondrial health, CNM-Au8® stands out among other therapies by targeting the nicotinamide adenine dinucleotide pathway to restore and protect neurological function. Nearly 2 million Americans are affected by amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”) or Parkinson’s disease. The global therapeutics markets for neurogenerative diseases are projected to grow substantially, driven by the growing prevalence of these conditions, rising geriatric population and the emergence of new therapies. Clene is preparing Phase 3 trials of CNM-Au8 in MS and ALS. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function…

WednesdaySep 04, 2024 10:00 am

New Approach Could Boost Effectiveness of Immunotherapies Against Colorectal Cancer

Colorectal cancer presents in many forms, with the most common type being microsatellite-stable colorectal cancer. This cancer type is common in the initial stages of colon cancer and rectal cancer, occurring in roughly 85% of colorectal cancers. Unlike patients with microsatellite unstable colorectal cancer, patients with this cancer respond to few immunotherapies designed to activate their immune systems to fight the cancer. Now new research has determined a potential cause of other therapies failing and found a way to improve the treatment for patients with this indication. The study was led by Victoria Stary from MedUni Vienna’s Comprehensive Cancer Center.…

WednesdaySep 04, 2024 9:45 am

Astiva Health Inc. Unveils New Community Outreach Initiative to Enhance Senior Wellness, Access to Care

The company is leveraging its extensive network of local partnerships to bring healthcare services directly into communities it serves Astiva is expanding network of activity centers, which are designed to be more than just places for medical care Astiva Health recognizes that true wellness goes beyond treating illness; it requires a proactive approach to health One of the pillars of Astiva Health’s approach to care is cultural responsiveness As the landscape of healthcare continues to shift toward more community-focused and personalized care, Astiva Health is launching a comprehensive community outreach initiative aimed at improving wellness and healthcare access for seniors across Southern…